Phase 3 Herniorrhaphy Study for Postoperative Analgesia (EPOCH 2)

Completed · Phase 3 · Has a placebo group

Conditions studied: Postoperative Pain

In brief

This is a Phase 3, randomized, double-blind, saline placebo- and active-controlled, multicenter study to evaluate the analgesic efficacy and safety of HTX 011 administered via local administration into the surgical site in subjects undergoing unilateral open inguinal herniorrhaphy.

Key facts

Study ID: NCT03237481
Run by: Heron Therapeutics
People needed: 418
Starts: 2017-07-31
Expected to finish: 2018-01-16
Last updated by the study team: 2026-03-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Is scheduled to undergo a unilateral open inguinal herniorrhaphy with mesh under general anesthesia.
Has an American Society of Anesthesiologists Physical Status of I, II, or III.
Female subjects are eligible only if not pregnant, not lactating, not planning to become pregnant during the study, sterile; or using acceptable contraceptives.

You may not qualify if…

Had any prior inguinal hernia repair.
Has a planned concurrent surgical procedure.
Has other pre existing concurrent acute or chronic painful physical/restrictive condition expected to require analgesic treatment in the postoperative period for pain.
Has a contraindication or a known or suspected history of hypersensitivity or clinically significant idiosyncratic reaction to required study medications.
Has known or suspected daily use of opioids for 7 or more consecutive days within the previous 6 months.
Has taken NSAIDs within 10 days prior to the scheduled surgery.
Has taken opioids within 24 hours prior to the scheduled surgery (3 days for long-acting).
Has been administered bupivacaine within 5 days prior to the scheduled surgery.
Has initiated treatment with medications within 1 month prior to study drug administration that can impact pain control.
Has been administered systemic steroids within 5 half-lives or 10 days prior to administration of study drug.
Has a medical condition such that, in the opinion of the Investigator, participating in the study would pose a health risk to the subject or confound the postoperative assessments.
Has a known history of Hepatitis B, human immunodeficiency virus (HIV), or active Hepatitis C.
Has uncontrolled anxiety, psychiatric, or neurological disorder that, in the opinion of the Investigator, might interfere with study assessments.
Had a malignancy in the last year, with the exception of nonmetastatic basal cell or squamous cell carcinoma of the skin or localized carcinoma in situ of the cervix.
Has a known or suspected history of drug abuse, a positive drug screen on the day of surgery, or a recent history of alcohol abuse. Note: Subjects with a positive drug screen who are taking an allowed, prescribed medication that is known to result in a positive drug test (eg, amphetamine and dextroamphetamine for attention deficit/hyperactivity disorder) may be eligible for participation in the study. Subjects taking medical marijuana are not allowed to participate in the study.
Received an investigational product or device in a clinical trial within 30 days or within 5 elimination half lives.
Has undergone 3 or more surgeries within 12 months.
Has a body mass index (BMI) >39 kg/m2.

Where it is running

Eliza Coffee Memorial Hospital — Florence, Alabama, United States
Shoals Medical Trials, Inc. — Sheffield, Alabama, United States
Arizona Research Center — Phoenix, Arizona, United States
Anaheim Clinical Trials, LLC — Anaheim, California, United States
Trovare Clinical Research, Inc. — Bakersfield, California, United States
Alliance Research Centers — Laguna Hills, California, United States
Lotus Clinical Research, LLC — Pasadena, California, United States
HD Research Corp — Riverside, California, United States
American Institute of Research — Whittier, California, United States
Yale University School of Medicine — New Haven, Connecticut, United States
Cornerstone Research Institute, LLC — Longwood, Florida, United States
Park Place Surgery Center — Maitland, Florida, United States
University of Miami — Miami, Florida, United States
St. Louis Clinical Trials — St Louis, Missouri, United States
eStudySite — Las Vegas, Nevada, United States
Midwest Clinical Research — Dayton, Ohio, United States
Hermann Drive Surgical Hospital — Houston, Texas, United States
Westside Surgical Hospital — Houston, Texas, United States
Plano Surgical Hospital — Plano, Texas, United States
Endeavor Clinical Trials, P.A. — San Antonio, Texas, United States
EPIC Medical Research, LLC — Murray, Utah, United States
Jean Brown Research — Salt Lake City, Utah, United States
Jessa Ziekenhuis — Hasselt, Limburg, Belgium
Ziekenhuis Oost Limburg — Genk, Belgium

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.